Results 271 to 280 of about 8,814,223 (344)

Impact of Pain Education on Pain Relief in Oncological Patients: A Narrative Review of Systematic Reviews and Meta-Analyses. [PDF]

Cancers (Basel)
Galietta E, Donati CM, Bazzocchi A, Sassi R, Zamfir AA, Hovenier R, Bos C, Hendriks N, Boomsma MF, Huhtala M, Blanco Sequeiros R, Grüll H, Ferdinandus S, Verkooijen HM, Morganti AG.   +14 more
europepmc   +1 more source

Book Reviews [PDF]

, 1984
Reviews, Book
core   +2 more sources

Interplay of integrins and selectins in metastasis

Molecular Oncology, EarlyView.
Here we review the role of integrins and their interplay with selectins in metastasis. The efficacy of integrin‐targeted therapies may be reduced in tumors where metastasis relies heavily on selectins. In certain tumors, integrins and selectins exhibit a synergistic interaction during intraperitoneal dissemination.
Diana Maltseva, Ashot Nersisyan, Alexander Tonevitsky   +2 more
wiley   +1 more source

The emergence of large language models as tools in literature reviews: a large language model-assisted systematic review. [PDF]

J Am Med Inform Assoc
Scherbakov D, Hubig N, Jansari V, Bakumenko A, Lenert LA.   +4 more
europepmc   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

BOOK REVIEWS

, 1928
NULL AUTHOR_ID
openalex   +1 more source

Telehealth Interventions in Pharmacy Practice: Systematic Review of Reviews and Recommendations.

J Med Internet Res
Chong RLK, Chan ASE, Chua CMS, Lai YF.
europepmc   +1 more source

Critically appraising the cass report: methodological flaws and unsupported claims. [PDF]

BMC Med Res Methodol
Noone C, Southgate A, Ashman A, Quinn É, Comer D, Shrewsbury D, Ashley F, Hartland J, Paschedag J, Gilmore J, Kennedy N, Woolley TE, Heath R, Goulding R, Simpson V, Kiely E, Coll S, White M, Grijseels DM, Ouafik M, McLamore Q.   +20 more
europepmc   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

BOOK REVIEWS

, 1941
NULL AUTHOR_ID
openalex   +1 more source